Equivalency challenge: Evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model

Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan

Alan N. Gordon, John Fleagle, David Guthrie et al. · Journal of Clinical Oncology · 2001 · 1.2K citations

Medicine, Oncology, Pharmacology +16

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

Franco M. Muggia, John D. Hainsworth, Susan Jeffers et al. · Journal of Clinical Oncology · 1997 · 657 citations

Medicine, Oncology, Pharmacology +17

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

Beatrice Uziely, Susan Jeffers, Rut Isacson et al. · Journal of Clinical Oncology · 1995 · 478 citations

Medicine, Oncology, Pharmacology +15

Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer

Gregory J.R. Charrois, Theresa M. Allen · Biochimica et Biophysica Acta (BBA) - Biomembranes · 2004 · 288 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200)

David S. Alberts, Pengfei Liu, Sharon P. Wilczynski et al. · Gynecologic Oncology · 2007 · 117 citations

Medicine, Gynecology, Oncology +16